Article Text

Download PDFPDF

O29 Determination of homogenous subgroups of antiphospholipid syndrome: cluster analysis based on 509 cases
  1. Yann Nguyen1,
  2. Cécile Yelnik2,
  3. Nathalie Morel3,
  4. Romain Paule4,
  5. Pierre-Yves Hatron2,
  6. Romain Stammler3,
  7. Léo Plaçais3,
  8. Jean-Charles Piette5,
  9. Luc Mouthon3,
  10. Éric Hachulla2,
  11. Marc Lambert2,
  12. Véronique Le Guern3 and
  13. Nathalie Costedoat-Chalumeau3
  1. 1Dept. of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy
  2. 2Dept. of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille
  3. 3National Referral Centre for Rare Autoimmune and Systemic Diseases, Dept. of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris
  4. 4Dept. of Internal Medicine, Hôpital Foch, Suresnes
  5. 5Dept. of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France


Background Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome (CAPS). APS can be associated with other auto-immune diseases, such as systemic lupus erythematosus (SLE). We aimed to determine distinct homogenous phenotypes among APS patients, using a non-supervised hierarchical cluster analysis.

Methods We performed an observational, retrospective study on APS patients satisfying Sydney classification criteria and enrolled in the French multicentre ‘APS and SLE’ registry. The clustering process involved an unsupervised multiple correspondence analysis followed by hierarchical ascendant clustering analysis, using 27 selected variables to widely cover APS clinical and biological manifestations. Comparisons between different subgroups were performed with Chi-2 tests and ANOVAs.

Results We included 509 patients in the analyses, mainly women (78%). Mean (± SD) age at APS diagnosis was 36.3 ± 14.7 years, and mean follow-up duration after APS diagnosis was 10.3 ± 8.5 years. Cluster hierarchical classification yield in four homogenous groups of patients. Their main characteristics are described in table 1.

Abstract O29 Table 1

Main characteristics according to devised cluster (N=509)

  1. Cluster 1 (n=181) included mostly patients with venous thrombosis (78%) and premature births due to placenta insufficiency (14%) history, without associated auto–immune disease (only 2.2%).

  2. Cluster 2 (n=130) included older patients (mean 45.8 years), less frequently women (65% of women), with arterial events history (89%). Valvular involvement (21%), migraine (21%), livedo (35%), arterial hypertension (49%), and cardiovascular risk factors were relatively frequent.

  3. Cluster 3 (n=102) included younger patients, frequently women (mean 30.7 years; 92% women), with associated SLE (76%) or other autoimmune diseases (30%). They frequently had history of venous thrombosis (74%) and of pregnancy morbidity (36%). Thrombocytopenia (48%), haemolytic anaemia (14%), and lupus anticoagulant (84%) were frequent.

  4. Cluster 4 (n=96) included mainly patients with a history of CAPS (77%) and/or APS–associated nephropathy (93%), and pregnancy morbidity (36%). Renal hypertension (61%), livedo (36%), seizures (14%), valvular involvement (44%) and triple positivity (66%) were relatively frequent.

Conclusions Using an unsupervised clustering method, our study highlighted four distinct homogenous subgroups of APS patients that were predominantly venous; arterial; associated with SLE or other autoimmune disease; and microthrombotic. It confirms the underlying idea of heterogeneous pathophysiological mechanisms.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.